Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 8 of 15

  1. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  2. Morphine

    Hospital Authority, Hong Kong

    Respiratory Depression

    phase 2 small molecule active

    1 trial

  3. N-acetyl cysteine

    United Therapeutics Europe Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  4. N-acetylcysteine capsule

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  5. NBI-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  6. NBI-1117570-SCZ2035

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  7. NBI-5788

    NEUROCRINE BIOSCIENCES INC

    Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  8. NET-MS

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  9. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prodromal Schizophrenia

    phase 2 small molecule active

    1 trial

  10. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    2 trials

  11. NMDAE plus AIFA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  12. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  13. NeuroEPO

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  14. NurOwn (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Multiple Sclerosis, Chronic Progressive

    phase 2 mab completed

    1 trial

  15. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  16. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  17. OXY-APS

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial

  18. Obexelimab

    Zenas BioPharma

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  19. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  20. PEG-liposomal prednisolone sodium phosphate

    Lakefront Biotherapeutics NV

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  21. PIPE-307 Dose A

    Contineum Therapeutics

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  22. PRENUMBRA

    Clinuvel Europe Limited

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  23. PTC518-CNS-002-HD

    PTC THERAPEUTICS, INC.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

  24. PTC857-CNS-001-ALS

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  25. PTT101

    Alphapharm Pty Ltd

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  26. Pepinemab

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  27. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  28. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  29. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  30. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  31. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  32. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  33. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial

  34. Placebo

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  35. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Depression

    phase 2 small molecule terminated

    1 trial

  36. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  37. Placebo

    Teva Pharma GmbH

    Primary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  38. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  39. Placebo for ML-007C-MA bilayer tablet

    MapLight Therapeutics

    Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

    phase 2 small molecule active

    1 trial

  40. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  41. PrimeC

    NeuroSense Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  42. Proleukin

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  43. Psilocybin

    COGNITION THERAPEUTICS INC

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  44. RAP-219

    Rapport Therapeutics

    Focal Epilepsy

    phase 2 small molecule active

    1 trial

  45. RHB-104

    RedHill Biopharma

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  46. RO7046015, RO7046015

    Hoffmann-La Roche

    Early Idiopathic Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  47. RP5063

    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    Acute Schizophrenia

    phase 2 small molecule completed

    1 trial

  48. Radotinib HCl, Placebo for Radotinib HCl

    Alphapharm Pty Ltd

    Treatment of Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.